IO Biotech, Inc. financial data

Symbol
IOBT on Nasdaq
Location
Copenhagen, Denmark
Fiscal year end
31 December
Latest financial report
10-Q - Q3 2025 - 14 Nov 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 241% % -71%
Debt-to-equity 158% % 948%
Return On Equity -465% % -438%
Return On Assets -181% % -140%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 71,948,842 shares 9.2%
Common Stock, Shares, Outstanding 69,692,179 shares 5.8%
Entity Public Float $60,600,000 USD 95%
Common Stock, Value, Issued $70,000 USD 6.1%
Weighted Average Number of Shares Outstanding, Basic 66,941,964 shares 1.6%
Weighted Average Number of Shares Outstanding, Diluted 66,941,964 shares 1.6%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense $67,916,000 USD -5.8%
General and Administrative Expense $24,136,000 USD -0.72%
Operating Income (Loss) $92,052,000 USD 4.5%
Nonoperating Income (Expense) $2,748,000 USD -63%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest $89,304,000 USD -0.35%
Income Tax Expense (Benefit) $955,000 USD -171%
Net Income (Loss) Attributable to Parent $88,358,000 USD 2.2%
Earnings Per Share, Basic -1 USD/shares -13%
Earnings Per Share, Diluted -1 USD/shares -13%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value $30,664,000 USD -62%
Assets, Current $36,831,000 USD -57%
Property, Plant and Equipment, Net $544,000 USD -22%
Operating Lease, Right-of-Use Asset $1,302,000 USD -28%
Other Assets, Noncurrent $1,011,000 USD 9.4%
Assets $39,956,000 USD -56%
Accounts Payable, Current $5,587,000 USD 6.3%
Employee-related Liabilities, Current $2,986,000 USD -16%
Liabilities, Current $18,311,000 USD 14%
Operating Lease, Liability, Noncurrent $667,000 USD -50%
Liabilities $39,045,000 USD 125%
Accumulated Other Comprehensive Income (Loss), Net of Tax $7,165,000 USD 35%
Retained Earnings (Accumulated Deficit) $416,329,000 USD -27%
Stockholders' Equity Attributable to Parent $911,000 USD -99%
Liabilities and Equity $39,956,000 USD -56%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities $23,071,000 USD 7.5%
Net Cash Provided by (Used in) Financing Activities $0 USD
Net Cash Provided by (Used in) Investing Activities $28,000 USD -155%
Common Stock, Shares Authorized 300,000,000 shares 0%
Common Stock, Shares, Issued 69,692,179 shares 5.8%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Deferred Tax Assets, Valuation Allowance $77,152,000 USD 33%
Deferred Tax Assets, Gross $77,567,000 USD 33%
Depreciation $61,000 USD -1.6%
Payments to Acquire Property, Plant, and Equipment $28,000 USD 155%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent $84,514,000 USD 7.6%
Lessee, Operating Lease, Liability, to be Paid $1,441,000 USD -35%
Operating Lease, Liability, Current $788,000 USD 14%
Lessee, Operating Lease, Liability, to be Paid, Year Two $423,000 USD -47%
Lessee, Operating Lease, Liability, to be Paid, Year One $818,000 USD 2.8%
Operating Lease, Weighted Average Discount Rate, Percent 0.06 pure 0%
Lessee, Operating Lease, Liability, to be Paid, Year Three $0 USD -100%
Deferred Tax Assets, Operating Loss Carryforwards $66,726,000 USD 33%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 5,000,000 shares 0%
Unrecognized Tax Benefits $0 USD
Lessee, Operating Lease, Liability, to be Paid, Year Four $0 USD
Operating Lease, Payments $208,000 USD 7.8%
Additional Paid in Capital $424,335,000 USD 3.1%
Preferred Stock, Shares Outstanding 0 shares
Depreciation, Depletion and Amortization $300,000 USD 20%
Deferred Tax Assets, Net of Valuation Allowance $415,000 USD -13%
Share-based Payment Arrangement, Expense $6,286,000 USD -2.5%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%